Cyclometalated iridium(III) complexes as mitochondria-targeted anticancer agents

Area of Science:

• Organometallic Chemistry
• Medicinal Chemistry
• Cancer Biology

Background:

• Cisplatin is a widely used chemotherapy drug but suffers from resistance and side effects.
• Targeting mitochondria offers a promising strategy for cancer therapy due to its crucial role in cell survival and apoptosis.
• Developing novel metal-based anticancer agents with improved selectivity and efficacy is an ongoing challenge.

Purpose of the Study:

• To synthesize and characterize novel cyclometalated iridium(III) complexes.
• To evaluate the anticancer activity of these complexes, particularly against cisplatin-resistant cancer cell lines.
• To investigate the cellular uptake mechanisms and selectivity of the iridium(III) complexes.

Main Methods:

• Synthesis and characterization of four iridium(III) complexes: Ir1, Ir2, Ir3, and Ir4.
• In vitro evaluation of cytotoxicity against various cancer cell lines and normal cells.
• Inductively Coupled Plasma Mass Spectrometry (ICP-MS) for cellular uptake studies.
• Apoptosis assays and analysis of signaling pathways.

Main Results:

• The synthesized iridium(III) complexes [Ir(dfppy)2(L)](+) selectively targeted cancer cell mitochondria.
• These complexes induced apoptosis in multiple cancer cell lines, including cisplatin-resistant ones.
• Differential cellular uptake mechanisms were observed between cancer and normal cells, leading to high selectivity.
• Structure-activity relationships and involved signaling pathways were elucidated.

Conclusions:

• The novel iridium(III) complexes exhibit potent and selective anticancer activity by targeting mitochondria.
• These complexes represent promising candidates for overcoming cisplatin resistance in cancer therapy.
• Further investigation into their therapeutic potential and mechanism of action is warranted.